These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24793366)

  • 1. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.
    Kosten TR; Domingo CB; Shorter D; Orson F; Green C; Somoza E; Sekerka R; Levin FR; Mariani JJ; Stitzer M; Tompkins DA; Rotrosen J; Thakkar V; Smoak B; Kampman K
    Drug Alcohol Depend; 2014 Jul; 140():42-7. PubMed ID: 24793366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
    Martell BA; Orson FM; Poling J; Mitchell E; Rossen RD; Gardner T; Kosten TR
    Arch Gen Psychiatry; 2009 Oct; 66(10):1116-23. PubMed ID: 19805702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine pharmacotherapy for the treatment of cocaine dependence.
    Martell BA; Mitchell E; Poling J; Gonsai K; Kosten TR
    Biol Psychiatry; 2005 Jul; 58(2):158-64. PubMed ID: 16038686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DBH gene as predictor of response in a cocaine vaccine clinical trial.
    Kosten TR; Domingo CB; Hamon SC; Nielsen DA
    Neurosci Lett; 2013 Apr; 541():29-33. PubMed ID: 23458673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human therapeutic cocaine vaccine: safety and immunogenicity.
    Kosten TR; Rosen M; Bond J; Settles M; Roberts JS; Shields J; Jack L; Fox B
    Vaccine; 2002 Jan; 20(7-8):1196-204. PubMed ID: 11803082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine.
    Orson FM; Rossen RD; Shen X; Lopez AY; Wu Y; Kosten TR
    Am J Addict; 2013; 22(2):169-74. PubMed ID: 23414504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.
    Somoza EC; Winship D; Gorodetzky CW; Lewis D; Ciraulo DA; Galloway GP; Segal SD; Sheehan M; Roache JD; Bickel WK; Jasinski D; Watson DW; Miller SR; Somoza P; Winhusen T
    JAMA Psychiatry; 2013 Jun; 70(6):630-7. PubMed ID: 23575810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized placebo-controlled trial of gabapentin for cocaine dependence.
    Bisaga A; Aharonovich E; Garawi F; Levin FR; Rubin E; Raby WN; Nunes EV
    Drug Alcohol Depend; 2006 Feb; 81(3):267-74. PubMed ID: 16169160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.
    Brodie JD; Case BG; Figueroa E; Dewey SL; Robinson JA; Wanderling JA; Laska EM
    Am J Psychiatry; 2009 Nov; 166(11):1269-77. PubMed ID: 19651710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial.
    Yuki Y; Nojima M; Hosono O; Tanaka H; Kimura Y; Satoh T; Imoto S; Uematsu S; Kurokawa S; Kashima K; Mejima M; Nakahashi-Ouchida R; Uchida Y; Marui T; Yoshikawa N; Nagamura F; Fujihashi K; Kiyono H
    Lancet Microbe; 2021 Sep; 2(9):e429-e440. PubMed ID: 35544149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.